Roche returns to Hansoh: $400 million upfront for an ADC platform and early pipeline

Data as of 2026-10-21 (Taipei time). [Fact] statements are sourced; [Inference] statements are this article's judgment.

1. One-line conclusion

[Fact] Roche's committed payments are US$400 million upfront plus a US$110 million first-anniversary payment, with milestones potentially exceeding US$15 billion (Hansoh). [Inference] In substance, Roche is using US$510 million in committed payments to buy from Hansoh an ADC production line in which "Roche proposes the targets and Hansoh takes them through global Phase Ia." The US$15 billion-plus in milestones is a ceiling, not an expected value. For sponsors, the most direct implication is that more Chinese ADCs will enter global development with US–China Phase Ia data, making GU ADC trials more crowded.

2. What happened

[Fact] On 2026-10-19 Hansoh announced a second ADC collaboration and license agreement with Roche (Hansoh).

• Assets: two Hansoh preclinical ADCs, plus multiple programs against Roche-proposed targets developed on Hansoh's ADC platform (Hansoh).
• Division of labor: Hansoh leads early development through completion of global Phase Ia; Roche then leads global development outside mainland China, Hong Kong, Macau and Taiwan; Hansoh retains all rights in those regions (Hansoh).
• Economics: US$400 million upfront and a US$110 million first-anniversary payment; development, regulatory and commercial milestones potentially exceeding US$15 billion; plus tiered royalties (Hansoh).
• Option: Hansoh may opt to fund development outside Greater China for up to two programs, in exchange for additional economics from US commercialization of those two programs (Hansoh).
• Prior deal: a year ago Roche paid US$80 million upfront, with up to US$1.45 billion in milestones, for ex-China rights to the CDH17 ADC HS-20110 (Fierce).
• Targets, indications, payload and linker: not found. This is a deal; there is no HR, CI or p value.

3. Why it matters

• [Inference] Committed payments are a tiny share: US$510 million against US$15 billion-plus, about 3%. Roche's upfront risk is small; Hansoh gets cash and platform validation.
• [Inference] A "Roche-proposed targets" model is taking shape: big pharma no longer just picks existing Chinese molecules but proposes targets for a Chinese platform to design against, with the Chinese partner running Phase Ia. It is not a one-off: [Fact] on 2026-08-28 Genentech (Roche Group) signed with DualityBio, which will develop ADCs against Genentech-defined targets on its DUPAC platform and lead early global clinical development, with Genentech taking over after Phase 1a (DualityBio). [Inference] This effectively outsources early R&D, and the Roche Group has now done it at least twice; whether Chinese biotech is broadly becoming big pharma's outsourced early R&D cannot be concluded from these cases alone.
• [Inference] The Phase Ia handoff point matters: Phase Ia covers only dose escalation, without expansion cohorts or full RP2D confirmation. Roche will still have to run its own Phase Ib/II dose optimization, and FDA's Project Optimus expectations will fall on Roche.
• External validation of Hansoh's ADCs: [Fact] ris-rez, the B7-H3 ADC GSK licensed from Hansoh, showed a median OS of 18.5 months in a Chinese Phase 3 (Fierce). This adds credibility to Hansoh's platform but does not mean new programs will succeed.

4. Regulatory and commercial implications

• FDA: [Inference] Whether Phase Ia data generated in China can support US dose selection after IND depends on whether US patients are enrolled in parallel; Hansoh's text says "global" Phase Ia, suggesting it is likely US–China.
• NMPA: Hansoh retains Greater China rights, so China will be a parallel, independent development path.
• Geopolitics: [Inference] US policy risk toward Chinese biotech (e.g., BIOSECURE-type legislation) is a long-tail risk for such deals; no clause directly related to this deal was found.
• Competition: [Fact] ADCs have moved heavily into urologic oncology, e.g., the B7-H3 ADC ifinatamab deruxtecan (I-DXd) Phase 3 in metastatic prostate cancer MK-2400-001 (NCT06925737), the TROP2 ADC sacituzumab govitecan Phase 3 in urothelial carcinoma, TROPiCS-04 (NCT04527991; it missed its OS primary endpoint, median OS 10.3 vs 9.0 months, HR 0.86, 95% CI 0.73–1.02, P=0.087, Ann Oncol), and GSK's planned ris-rez prostate cancer Phase 3 (GSK). Roche has not disclosed targets; whether GU is among them: not found.
• For the next trial: [Inference] the deal does not change GU site selection in the near term, but as more Phase Ia work is led by Chinese partners, the follow-on Phase Ib/II dose-optimization trials will multiply and US/European sites with ADC experience will be booked tighter; sponsors should reserve capacity early.

5. Lessons for the next trial design and OncoLattice recommendations

All recommendations below are [Inference]; cited facts carry their own sources.

1. Plan the "China Phase Ia → global Phase Ib/II" handoff upfront: the receiving sponsor should run randomized dose optimization (at least two doses) in Phase Ib and collect sufficient PK and safety data in non-Asian patients.
2. Site strategy: Chinese Phase Ia sites often enroll fast, but global Phase Ib needs US and European sites experienced in managing ADC toxicities (ILD, ocular toxicity, neuropathy). Sponsors should map US and European GU sites with ADC-toxicity management experience early.
3. GU ADC trials are crowded: ADC trials in urothelial carcinoma and mCRPC will keep multiplying; lock in biomarker screening workflows (e.g., target IHC) and patient referral pathways early.
4. Until targets are disclosed, committing GU resources on account of this deal is not recommended.

6. Unknowns and what to watch

• The identity of the two preclinical programs and the Roche-proposed targets.
• When the first program enters global Phase Ia.
• Whether Hansoh exercises its co-development option for two programs.
• Global progress of HS-20110.

Evidence limitations

All terms come from Hansoh's release and Fierce; the full contract was not seen. The milestone total is a nominal ceiling with no disclosed breakdown. This article's views on the outsourcing model and policy risk are inference.

Endnote: differences from the original forwarded account

1. Hansoh's original text says "potentially more than US$15 billion"; Fierce says "up to $15 billion" (Hansoh, Fierce). The forwarded account's ">$15B" matches the company's wording; Fierce's phrasing is more conservative.
2. The forwarded account's "Hansoh through global Ph Ia" is correct, but Fierce writes "phase 1 trials" (Fierce), which is vaguer; Hansoh's original "Phase Ia" governs.
3. Hansoh's additional-economics option is limited to the US market (Hansoh); the forwarded account did not mention this.